SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Tatva Chintan Pharma - Quaterly Results

04 Aug 2023 Evaluate
The revenue for the June 2023 quarter is pegged at Rs. 1061.05 millions, about 23.28% up against Rs. 860.65 millions recorded during the year-ago period.The Company's Net profit for the June 2023 quarter have declined marginally to Rs. 82.48  millions as against Rs. 85.00 millions reported during the corresponding quarter ended.Operating profit surged to 206.28 millions from the corresponding previous quarter of 153.73 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 1061.05 860.65 23.28 1061.05 860.65 23.28 4030.44 4278.11 -5.79
Other Income 10.15 18.75 -45.87 10.15 18.75 -45.87 56.78 106.29 -46.58
PBIDT 206.28 153.73 34.18 206.28 153.73 34.18 603.56 1163.97 -48.15
Interest 28.98 10.64 172.37 28.98 10.64 172.37 83.84 49.51 69.34
PBDT 177.30 143.09 23.91 177.30 143.09 23.91 483.85 1114.46 -56.58
Depreciation 60.11 23.33 157.65 60.11 23.33 157.65 95.54 81.80 16.80
PBT 117.19 119.76 -2.15 117.19 119.76 -2.15 388.31 1032.66 -62.40
TAX 34.71 34.76 -0.14 34.71 34.76 -0.14 -16.34 72.79 -122.45
Deferred Tax 14.31 3.73 283.65 14.31 3.73 283.65 -35.93 -107.29 -66.51
PAT 82.48 85.00 -2.96 82.48 85.00 -2.96 404.65 959.87 -57.84
Equity 221.65 221.65 0.00 221.65 221.65 0.00 221.65 221.65 0.00
PBIDTM(%) 19.44 17.86 8.84 19.44 17.86 8.84 14.98 27.21 -44.96

Tatva Chintan Pharma Share Price

1275.10 -8.55 (-0.67%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3703.10
Tata Chemicals 709.05
SRF 2493.65
Pidilite Inds. 1393.25
Deepak Nitrite 1538.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×